Strides Targets $200m-$400m From Injectables

Biosimilars In Development Include Insulin Glargine And Lispro

 
• By Vibha Ravi
Growth
Strides Chalks Stelis' Growth Strategy • Source: Shutterstock

More from Strategy

More from Business